Levodopa/carbidopa Intestinal Gel Can Improve Both Motor and Non-Motor Experiences of Daily Living in Parkinson’s Disease: An Open-Label Study
Objective: : Our aim was to determine if the MDS-UPDRS and UDysRS could detect improvement in the experiences of daily living following 1-year LCIG treatment.…Tremor as the first symptom reported by Parkinson’s disease patients is a predictor of future motor subtype and levodopa-induced dyskinesia.
Objective: To better delineate risk profiles for the development of levodopa-induced dyskinesia is an important effort that can help understand this phenomenon and could impact…The SYNAPSES study (StudY to observe SafiNAmide in clinical Practice during the firSt post-commErcialization phaSe): methodology and results from the European feasibility survey
Objective: Here we present the design of a Drug Utilization Study of safinamide in the first post-commercialization phase and report results of the study feasibility…Intrajejunal levodopa infusion (ILI) for Parkinson’s Disease (PD): A Canadian Experience
Objective: To review the benefits and complications of ILI for PD in a tertiary movement disorders center in Canada. Background: ILI has been in use…The impact of gastric acid suppressants and antacids on levodopa plasma concentration in patients with Parkinson’s disease
Objective: The levodopa tablet is prone to dissolve in acidic conditions. We investigated whether gastric acid suppressants (histamine-2 receptor antagonists or proton pump inhibitors) and…Tremor-Dominant Clinical Phenotype is Associated with Low Risk of Levodopa-Induced Dyskinesia in Parkinson’s Disease
Objective: To evaluate possible associations between epidemiological and clinical data with risk of levodopa-induced dyskinesias (LID) onset in Parkinson’s disease (PD) patients. Background: LID are…Diphasic Dyskinesias during levodopa-carbidopa intestinal gel (LCIG) infusion: diagnosis and management in clinical practice.
Objective: To describe the occurrence, diagnostic approach, clinical management and outcome of diphasic dyskinesias (Dyskinesias-Improvement-Dyskinesias, DID) in a large group of Parkinson’s Disaese (PD) patients…Pharmacokinetic profile of continuous levodopa/carbidopa delivery when administered subcutaneously (ND0612) versus duodenal infusion (levodopa/carbidopa intestinal gel)
Objective: To compare levodopa PK, derived from ND0612 (a proprietary liquid levodopa/carbidopa formulation designed for subcutaneous (SC) administration) with Levodopa/Carbidopa Intestinal Gel (LCIG). Background: While…Central Aortic Pressure in Parkinson’s Disease and Levodopa Effect
Objective: Central aortic pressure (CAP) is the systolic blood pressure at the root of the aorta. In young people CAP is lower than the peripheral…Managing severe dyskinesia in Parkinson’s Disease using 24-hour Levodopa/Carbidopa Intestinal Gel Infusion
Objective: We report the effective treatment of troublesome dyskinesias in Parkinson’s disease (PD), unresponsive to 16-hour daytime infusions, using 24-hour Levodopa/Carbidopa Intestinal Gel (LCIG). Background:…
- « Previous Page
- 1
- …
- 48
- 49
- 50
- 51
- 52
- …
- 62
- Next Page »